Issue

Vol. 66 No. 1: Issue 1

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Antitumor mechanism of MAP30 in bladder cancer T24 cells, and its potential toxic effects in mice

https://doi.org/10.14715/cmb/2019.66.1.7
Zhenduo Shi
Urology Surgery, Xuzhou Central Hospital, Xuzhou City, Jiangsu Province, China
Kun Pang
Urology Surgery, Xuzhou Central Hospital, Xuzhou City, Jiangsu Province, China
Wen Yang
Nephrology, Affiliated Hospital of Shandong Academy of Medical Sciences ,Jinan City,Shandong Province, China
Jiahe Zhou
Urology Surgery, Xuzhou Central Hospital, Xuzhou City, Jiangsu Province, China
Bingzheng Dong
Urology Surgery, Xuzhou Central Hospital, Xuzhou City, Jiangsu Province, China
Zhiguo Zhang
Urology Surgery, Xuzhou Central Hospital, Xuzhou City, Jiangsu Province, China
Yan Zhao
Urology Surgery, Xuzhou Central Hospital, Xuzhou City, Jiangsu Province, China
Conghui Han
Urology Surgery, Xuzhou Central Hospital, Xuzhou City, Jiangsu Province, China
Lin Hao
Urology Surgery, Xuzhou Central Hospital, Xuzhou City, Jiangsu Province, China

Corresponding Author(s) : Conghui Han

xnag69@163.com

Cellular and Molecular Biology, Vol. 66 No. 1: Issue 1

Abstract

To investigate the antitumor mechanism of MAP30 in human bladder cell line (T24) and its potential toxic effects in mice.  In this study, the biological behavior of MAP30's influence on bladder cell was investigated to reveal the antitumor mechanism and role of MAP30 in bladder cancer. MAP30 gene sequence optimized by gene synthesis codon was inserted into the prokaryotic expression vector pET-28a to produce a large amount of target protein in Escherichia coli. The protein product was obtained after purification. Membrane hydration method was used to prepare MAP30 liposome in order to enhance its membrane permeability. The effects of MAP30 on the viability, apoptosis and migration of T24 cell were assessed using 3"‘(4,5"‘dimethyl"‘thiazol"‘2"‘yl)"‘2,5"‘diphenyl"‘2H"‘tetrazolium bromide (MTT), flow cytometric and TUNEL assays, respectively. Mice were transfected with bladder cancer cells for 48 h. The expressions of apoptotic and non-apoptotic proteins were determined using Western blotting. Changes in tumor volume and occurrence of metastasis were assessed using luciferase assay. After 7 days, liver and kidney were excised for histological examination. The levels of reactive oxygen species (ROS), malondialdehyde (MDA), and reduced glutathione (GSH), and activities of catalase and glutathione peroxidase (GPx) were determined in serum or homogenate using enzyme-linked immunosorbent assay (ELISA). The yield of MAP30 after purification was significantly increased. The results of MTT assay showed that MAP30 significantly and concentration-dependently inhibited the proliferation and migration of T24 cells (p < 0.05). The prepared liposomes had uniform hydrated particle size of 132.6 nm, with encapsulation efficiency of 78 %. The inhibitory effect of MAP30 liposome on T24 cells was significantly higher than that of MAP30, and MAP30 significantly increased the number of apoptotic cells (p < 0.05). Western blotting showed that MAP30 significantly promoted the expression of caspase 3 (p < 0.05), but did not significantly affect the expressions of bcl-2 and bax (p > 0.05). It also significantly down-regulated the expressions of NF-kB, JNK and MMP2 (p < 0.05). Tumor formation was significantly inhibited, and tumor volume reduced in bladder cancer-bearing mice after treatment with MAP30 (p < 0.05). Histological examination showed that MAP30 induced mild histological changes in the liver and kidney of mice, and significantly increased the level of MDA at day 1 (p < 0.05). It also significantly and time-dependently increased ROS, but reduced GSH levels and activities of catalase and GPx (p < 0.05). However, MAP30 had no significant effect on DNA (p > 0.05). The apoptotic effect of MAP30 in T24 cells is mediated via activation of caspase-3 signaling pathway. The protein produces mild histological changes in the liver and kidney of mice, but has no significant effect on DNA.


Keywords

Bladder cancer Bitter gourd MAP30 Apoptosis Toxicity.
Shi, Z., Pang, K., Yang, W., Zhou, J., Dong, B., Zhang, Z., Zhao, Y., Han, C., & Hao, L. (2020). Antitumor mechanism of MAP30 in bladder cancer T24 cells, and its potential toxic effects in mice. Cellular and Molecular Biology, 66(1), 42–48. https://doi.org/10.14715/cmb/2019.66.1.7
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Fang EF, Ng TB. Bitter gourd (Momordica charantia) is a cornucopia of health: a review of its credited antidiabetic, anti-HIV, and antitumor properties. Curr Mol Med 2011; 11: 417-436.
  2. Schaefer H, Renner SS. A three-genome phylogeny of Momordica (Cucurbitaceae) suggests seven returns from dioecy to monoecy and recent long-distance dispersal to Asia. Mol Phylogenet Evol 2010; 54: 553-560.
  3. Fang EF, Zhang CZ, Ng TB, Wong JH, Pan WL, Ye XJ, et al. Momordica Charantia Lectin, a Type II ribosome inactivating protein, exhibits antitumor activity toward human nasopharyngeal carcinoma cells in vitro and in vivo. Cancer Prev Res 2011; 5: 109-121.
  4. Fang EF, Zhang CZ, Fong WP, Ng TB. RNase MC2: a new Momordica charantia ribonuclease that induces apoptosis in breast cancer cells associated with activation of MAPKs and induction of caspase pathways. Apoptosis 2011; 17: 377-387.
  5. Xiong SD, Yu K, Liu XH, Yin LH, Kirschenbaum A, Yao S, et al. Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells. Int J Cancer 2009; 125: 774-782.
  6. Fang EF, Ng TB. Can bitter gourd (Momordica charantia) be a novel therapy for human cancers? Medicinal Aromatic Plants 2012; 1: 1-2.
  7. Fang EF, Ng TB, Shaw PC, Wong RNS. Recent progress in medicinal investigations on trichosanthin and other ribosome inactivating proteins from the plant genus trichosanthes. Curr Med Chem 2011; 18: 4410-4417.
  8. Lee HS, Huang PL, Nara PL, Chen HC, Kung HF, Huang P, et al. MAP 30: a new inhibitor of HIV-1 infection and replication. FEBS Lett 1990; 272: 12-18.
  9. Bourinbaiar AS, Lee-Huang S. The activity of plant-derived antiretroviral proteins MAP30 and GAP31 against herpes simplex virus in vitro. Biochem Biophys Res Commun 1996; 219: 923-929.
  10. Lee-Huang S, Huang PL, Bourinbaiar AS, Chen HC, Kung HF. Inhibition of the integrase of human immunodeficiency virus (HIV) type 1 by anti-HIV plant proteins MAP30 and GAP31. Proc Natl Acad Sci USA 1995; 92: 8818-8822.
  11. Wang YX, Neamati N, Jacob J, Palmer I, Stahl SJ, Kaufman JD, et al. Solution structure of anti-HIV-1 and anti-tumor protein MAP30: structural insights into its multiple functions. Cell 1999; 99: 433-442.
  12. Sun Y, Huang PL, Li JJ, Huang YQ, Zhang L, Lee-Huang S. Anti-HIV agent MAP30 modulates the expression profile of viral and cellular genes for proliferation and apoptosis in AIDS-related lymphoma cells infected with Kaposi's sarcoma-associated virus. Biochem Biophys Res Commun 2001; 287: 983-994.
  13. Arazi T, LeeHuang P, Huang PL, Zhang L, Moshe-Shiboleth Y, Gal-On A, et al. Production of antiviral and antitumor proteins MAP30 and GAP31 in cucurbits using the plant virus vector ZYMV-AGII. Biochem Biophys Res Commun 2002; 292: 441-448.
  14. Lee-Huang S, Huang PL, Chen HC, Bourinbaiar A, Huang HI, Kung HF. Anti-HIV and anti-tumor activities of recombinant MAP30 from bitter melon. Gene 1995; 161: 151-156.
  15. Huang PL, Sun Y, Chen HC, Kung HF, Lee-Huang S. Proteolytic fragments of anti-HIV and anti-tumor proteins MAP30 and GAP31 are biologically active. Biochem Biophys Res Commun 1999; 262: 615-623.
  16. Fan JM, Luo J, Xu J, Zhu S, Zhang Q, Gao DF, et al. Effects of recombinant MAP30 on cell proliferation and apoptosis of human colorectal carcinoma LoVo cells. Mol Biotechnol 2008; 39: 79-86.
  17. Hao L, Zhang ZG, Han CH. Expression of Momordica charantia MAP30 and its anti-tumor effect on bladder cancer cells. Minerva Urologica E Nefrologica 2014; 68: 275.
  18. Kong KL, Kwong DL, Fu L, Chan TH, Chen L, Liu H, et al. Characterization of a candidate tumor suppressor gene uroplakin 1A in esophageal squamous cell carcinoma. Cancer Res 2010; 70: 8832-8841.
  19. Zhang CZ, Zhang HT, Chen GG, Lai PB. Trichostatin A sensitizes HBx expressing liver cancer cells to etoposide treatment. Apoptosis 2011; 16: 683-695.
  20. Kelly PN, Strasser, A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ 2011; 18: 1414-1424.
  21. Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, et al. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Update 2007; 10: 13-29.
  22. Krajewski S, Krajewska M, Ellerby LM, Welsh K, Xie Z, Deveraux QL, et al. Release of caspase-9 from mitochondria during neuronal apoptosis and cerebral ischemia. Proc Natl Acad Sci USA 1999; 96: 5752-5757.
  23. Seoane S, Montero JC, Ocana A, Pandiella A. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells. J Natl Cancer Inst 2010; 102: 1432-1446.
  24. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004: 64: 7099-7109.
  25. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
  26. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127.
  27. Schreiber CA, Wan L, Sun Y, Lu L, Krey LC, Lee-Huang S. The antiviral agents, MAP30 and GAP31, are not toxic to human spermatozoa and may be useful in preventing the sexual transmission of human immunodeficiency virus type 1. Fertil Steril 1999; 72: 686-690.
  28. Putnam CD, Tainer JA. The food of sweet and bitter fancy. Nat Struct Biol 2000; 7: 17-18.
  29. Ray RB, Raychoudhuri A, Steele R, Nerurkar P. Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Res 2010; 70: 1925-1931.
  30. Brennan VC, Wang CM, Yang WH. Bitter melon (Momordica charantia) extract suppresses adrenocortical cancer cell proliferation through modulation of the apoptotic pathway, steroidogenesis, and insulin-like growth factor Type 1 receptor/RAC-alpha serine/threonine-protein kinase signaling. J Med Food 2012; 15: 325-334.
  31. Ru P, Steele R, Nerurkar PV, Phillips N, Ray RB. Bitter melon extract impairs prostate cancer cell-cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model. Cancer Prev Res 2011; 4: 2122-2130.
  32. Lee YI, Lee S, Das GC, Park US, Park SM. Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-offunction during the formation of hepatocellular carcinoma. Oncogene 2000; 19: 3717-3726.
  33. Ohnishi K, Ota I, Takahashi A, Yane K, Matsumoto H, Ohnishi T. Transfection of mutant p53 gene depresses X-ray- or CDDP-induced apoptosis in a human squamous cell carcinoma of the head and neck. Apoptosis 2002; 7: 367-372.
  34. Hsu IC, Tokiwa T, Bennett W, Metcalf RA, Welsh JA, Sun T, et al. P53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 1993; 14: 987-992.
  35. Kanashiro CA, Schally AV, Groot K, Armatis P, Bernardino AL, Varga JL. Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin. Proc Natl Acad Sci USA 2003; 100: 15836-15841.
  36. Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S, et al. Role of poly (ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 1999; 274: 22932-22940.
  37. Shimizu S, Narita M, Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 1999; 399: 483-487.
  38. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-442.
  39. Ng SS, Tsao MS, Nicklee T, Hedley DW. Wortmannin inhibits PKB/AKT phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res 2001; 7: 3269-3275.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 912 Download : 519